In 2020, the coronavirus epidemic broke out in Hungary. We immediately set out to help with our knowledge and strength in epidemic control; with the innovative development of COVID-19 diagnostics and therapy on a single platform. In the era of epidemics, it is in Hungary's strategic interest to independently build and develop its biological defense capabilities. The COVID-19 epidemic has shown that significant biological defense capabilities are necessary for an effective and rapid response. ​Dr. Roland Hetényi and Dr. Dániel Hanna graduated from Nagy Lajos High School. With the only difference being that one of them was in Pécs, the other in Szombathely. They were already preparing for their final exams at the Faculty of General Medicine of the University of Pécs when the coronavirus pandemic hit. Roland Hetényi and Daniel Hanna decided to immediately start helping with their medical knowledge. They planned a project to measure the effectiveness of vaccines against the coronavirus. They came together years ago, while preparing for anatomy exams, and since then they have had many success stories. They developed university notes and prepared high school groups for advanced physics and chemistry exams. Among other things, they won the national legislative competition called Mint-A-Parlament twice with their team, and their bill was accepted by the Ministry of Health, thus creating the legal framework for lung cancer screening. Interestingly, Roland Hetényi's great-grandfather is Andor Nendtvich, who was the mayor of Pécs for 30 years. ​During the COVID-19 outbreak, while preparing for their final exams, they drew plans for the devices to be developed and wrote experimental descriptions at night. They obtained their diplomas in July 2020. In the meantime, they applied to the University of Pécs as PhD students and became research physicians at the Research, Development and Innovation Directorate of the National Blood Service (OVSZ). In order to quickly implement the solutions born from the challenge, RoLink Biotechnology Kft. was founded in August 2020. The primary goal of the startup is to develop the biological defense capability of our country. They received support from the COVID Fund of the Ministry of Innovation and Technology, started working immediately, and today they have 5 antiviral technologies and patents to their name. They work in close cooperation with the National Laboratory of Virology of the University of Pécs and are implementing the connection of the industrial and academic worlds in practice. RoLink Biotechnology Ltd. has already demonstrated the applicability of the technology in a clinical setting in its COVID project (2020-2.1.1-ED-2020-00100). The UV inactivation they developed is suitable for complete inactivation of viruses, thereby overcoming the capacity constraints of high-safety laboratories, and simultaneously creating a basis for diagnostic test development and vaccine development. Vaccine potential proven in animal experiments, diagnostic development proven in a clinical setting. According to news published in the media, they have recently received personal inquiries from large international organizations, and then from biotech companies, but since the beginning of the COVID epidemic and based on their beliefs, their main intention is to ensure that their knowledge and the technologies they have developed remain the privilege of our country.